Alpha Bio

A-Alpha Bio is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in measuring, predicting, and engineering protein-protein interactions to enhance therapeutic discovery and improve human health. A-Alpha Bio utilizes synthetic biology and machine learning technologies to analyze millions of protein interactions simultaneously, transforming biopharmaceutical research and development. The company offers two main platforms: AlphaSeq and AlphaBind. AlphaSeq is an experimental platform that allows for rapid, high-throughput measurement of protein-protein binding affinities, providing large-scale interaction data efficiently. AlphaBind is a computational platform that predicts binding strengths from protein sequences using machine learning, aiding in the design of novel protein interactions. A-Alpha Bio collaborates with pharmaceutical companies and research institutions to support drug discovery and development, focusing on molecular glues and engineered biologics, particularly in oncology and immunotherapy. With over $64 million in funding, A-Alpha Bio is expanding its therapeutic pipeline and strengthening its innovative platforms. The company has also filed multiple patents related to its work in protein interaction measurement and engineering.